Proactiveinvestors recommends
Additional Information
Market:ASX
Sector:Pharma & Biotech
EPIC:RHT
Latest Price: 0.01  (0.00%)
52-week High:0.03
52-week Low:0.01
Market Cap:4.33M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Resonance Health

Resonance Health (ASX: RHT) is an Australian healthcare company specialising in the development and commercialisation of magnetic resonance imaging (MRI) related technology for the diagnosis and management of human disease.

Pdf

Resonance Health develops accurate fatty liver diagnostic test, seeks FDA approval

Monday, May 23, 2011
Resonance Health develops accurate fatty liver diagnostic test, seeks FDA approval

Resonance Health (ASX: RHT) has developed a fatty liver diagnostic test after positive results from a clinical study accurately assessed the severity of the disease.

Results from the clinical study demonstrate that the MRI-based diagnostic product developed by the company can accurately assess the severity of fatty liver disease, replacing the costly and time-consuming need for an invasive liver biopsy.

The company has begun preparation of a Food and Drug Administration submission to gain regulatory approval for the product.

The clinical study involved 46 subjects with liver disease, including non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and Hepatitis C.

Each patient underwent a liver biopsy with the degree of liver fat scored by two independent methods and compared to the MRI-based result, showing a high level of sensitivity and specificity for the test.

According to Resonance, nearly one in three Americans have fatty liver, and non-alcoholic fatty liver disease is the most common liver disease in the US and Europe.

An accurate diagnosis of early stage fatty liver disease provides a better outcome for patients, to address the condition before the onset of liver damage.

 

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.